OXURION_logo.png
Oxurion To Participate in Upcoming Investor Conferences
October 18, 2022 13:00 ET | Oxurion NV
Leuven, BELGIUM, Boston, MA, US – October 18, 2022 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...
Informatie met betre
Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie
September 30, 2022 13:00 ET | Oxurion NV
Negma Group heeft 160 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 400.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen...
Information on the T
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
September 30, 2022 13:00 ET | Oxurion NV
Negma Group has converted 160 convertible bonds in Oxurion resulting in a EUR 400,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to...
OXURION_logo.png
Oxurion To Participate in Upcoming Scientific and Investor Conferences
September 12, 2022 13:00 ET | Oxurion NV
Leuven, BELGIUM, Boston, MA, US – September 12, 2022 – 7.00 PM CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...
Oxurion maakte halfj
Oxurion maakte halfjaarresultaten 2022 bekend
September 07, 2022 02:25 ET | Oxurion NV
Leuven, BELGIË, Boston, MA, VS - 7 september 2022 – 8.00 CET Oxurion NV (Euronext Brussels: OXUR), een biofarmaceutisch bedrijf dat dat oogheelkundige standaardbehandelingen van de volgende generatie...
Oxurion Publishes Fi
Oxurion Publishes First Half 2022 Results
September 07, 2022 02:25 ET | Oxurion NV
Leuven, BELGIUM, Boston, MA, US – September 7, 2022 – 8.00 am CET Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...
OXURION_logo.png
Oxurion Announces Amendment to Funding Program with Negma Group for EUR 6 Million in Funding
September 02, 2022 17:00 ET | Oxurion NV
Leuven, BELGIUM, Boston, MA, US – September 2, 2022 – CET 10:30PM – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies,...
Informatie met betre
Informatie met betrekking tot het Totaal Aantal Stemrechten (Noemer) volgend op NEGMA Conversie-Notificatie
August 26, 2022 13:00 ET | Oxurion NV
Negma Group heeft 200 converteerbare obligaties in Oxurion geconverteerd resulterende in een kapitaalverhoging van EUR 500.000. Deze conversie vormt deel van Negma Group’s EUR 30 miljoen...
Information on the T
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from NEGMA
August 26, 2022 13:00 ET | Oxurion NV
Negma Group has converted 200 convertible bonds in Oxurion resulting in a EUR 500,000 capital increase. This is part of Negma Group’s EUR 30 million Capital Commitment1 that will allow Oxurion to...
OXURION_logo.png
Oxurion To Present at Upcoming Scientific and Investor Conferences
August 24, 2022 13:00 ET | Oxurion NV
Leuven, BELGIUM, Boston, MA, US – August 24, 2022 – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical...